Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer. Founded by Matthew Shair in 2017, Nuvalent is backed by investors that include Deerfield Management and is headquartered in Cambridge.
FOUNDED:
2017
INDUSTRY:
Biotechnology, Life Science, Therapeutics
FOUNDERS:
Matthew Shair
You are seconds away from signing up for the hottest list in New York Tech!
Join the millions and keep up with the stories shaping entrepreneurship. Sign up today.
